98-16503. Agency Information Collection Activities: Proposed Collection; Comment Request  

  • [Federal Register Volume 63, Number 119 (Monday, June 22, 1998)]
    [Notices]
    [Pages 33933-33934]
    From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
    [FR Doc No: 98-16503]
    
    
    =======================================================================
    -----------------------------------------------------------------------
    
    DEPARTMENT OF HEALTH AND HUMAN SERVICES
    
    Food and Drug Administration
    [Docket No. 98N-0364]
    
    
    Agency Information Collection Activities: Proposed Collection; 
    Comment Request
    
    AGENCY: Food and Drug Administration, HHS.
    
    ACTION: Notice.
    
    -----------------------------------------------------------------------
    
    SUMMARY: The Food and Drug Administration (FDA) is announcing an 
    opportunity for public comment on the proposed collection of certain 
    information by the agency. Under the Paperwork Reduction Act of 1995 
    (the PRA), Federal agencies are required to publish notice in the 
    Federal Register concerning each proposed collection of information, 
    including each proposed reinstatement of an existing collection of 
    information, and to allow 60 days for public comment in response to the 
    notice. This notice solicits comments on product specific reports and 
    recordkeeping requirements for certain electronic products.
    
    DATES: Submit written comments on the collection of information by 
    August 21, 1998.
    
    ADDRESSES: Submit written comments on the collection of information to 
    the Dockets Management Branch (HFA-305), Food and Drug Administration, 
    12420 Parklawn Dr., rm. 1-23, Rockville, MD 20857. All comments should 
    be identified with the docket number found in brackets in the heading 
    of this document.
    
    FOR FURTHER INFORMATION CONTACT: Margaret R. Schlosburg, Office of 
    Information Resources Management (HFA-250), Food and Drug 
    Administration, 5600 Fishers Lane, Rockville, MD 20857, 301-827-1223.
    
    SUPPLEMENTARY INFORMATION: Under the PRA (44 U.S.C. 3501-3520), Federal 
    agencies must obtain approval from the Office of Management and Budget 
    (OMB) for each collection of information they conduct or sponsor. 
    ``Collection of information'' is defined in 44 U.S.C. 3502(3) and 5 CFR 
    1320.3(c) and includes agency requests or requirements that members of 
    the public submit reports, keep records, or provide information to a 
    third party. Section 3506(c)(2)(A) of the PRA (44 U.S.C. 3506(c)(2)(A)) 
    requires Federal agencies to provide a 60-day notice in the Federal 
    Register concerning each proposed collection of information, including 
    each proposed reinstatement of an existing collection of information, 
    before submitting the collection to OMB for approval. To comply with 
    this requirement, FDA is publishing notice of the proposed collection 
    of information listed below.
        With respect to the following collection of information, FDA 
    invites comments on: (1) Whether the proposed collection of information 
    is necessary for the proper performance of FDA's functions, including 
    whether the information will have practical utility; (2) the accuracy 
    of FDA's estimate of the burden of the proposed collection of 
    information, including the validity of the methodology and assumptions 
    used; (3) ways to enhance the quality, utility, and clarity of the 
    information to be collected; and (4) ways to minimize the burden of the 
    collection of information on respondents, including through the use of 
    automated collection techniques, when appropriate, and other forms of 
    information technology.
    
    Reporting and Recordkeeping for Electronic Products: Specific 
    Product Requirements 21 CFR Parts 1020, 1030, 1040, and 1050 (OMB 
    Control Number 0910-0213--Reinstatement)
    
        Under sections 532 to 542 of the Federal Food, Drug, and Cosmetic 
    Act (the act) (21 U.S.C. 360ii to 360ss), FDA has the responsibility to 
    protect the public from unnecessary exposure to radiation from 
    electronic products. Section 532 of the act (21 U.S.C. 360ii) directs 
    the Secretary of the Department of Health and Human Services (the 
    Secretary) to establish and carry out an electronic product radiation 
    control program designed to protect the public health and safety from 
    electronic radiation by, among other things, developing and 
    administering performance standards for electronic products. Section 
    534(g) of the act (21 U.S.C. 360kk(g)) directs the Secretary to review 
    and evaluate industry testing programs on a continuing basis; and 
    section 535(e) and (f) of the act (21 U.S.C. 360ll(e) and (f)) directs 
    the Secretary to immediately notify manufacturers of, and assure 
    correction of, radiation defects or noncompliance with performance 
    standards. The agency's authority to require records and reports is 
    contained in section 537(b) and (c) of the act (21 U.S.C. 360nn(b) and 
    (c)).
        Under this authority, FDA issued regulations detailing product-
    specific performance standards that specify information to be supplied 
    with the product or require specific reports.
        The information collections are either specifically called for in 
    the act or were developed to aid the agency in performing its 
    obligations under the act. The data reported to FDA and the records 
    that are maintained are used by FDA and the industry to make decisions 
    and take actions that protect the public from radiation hazards 
    presented by electronic products. This information refers to the 
    identification of, location of, operational characteristics of, quality 
    assurance programs for, and problem identification and correction of 
    electronic products. The data provided to users and others are intended 
    to encourage actions to reduce or eliminate radiation exposures.
        The consequence of not obtaining the required information is that 
    the public unknowingly may be exposed to unnecessary radiation hazards 
    presented by electronic products. Without this information, FDA could 
    not adequately make rational decisions and take appropriate actions to 
    protect the public from these hazards as called for in the act.
        Respondents to this collection of information are manufacturers, 
    importers, and assemblers of electronic products. Not all of the 
    requirements are placed on all of these groups.
        FDA estimates the burden of this collection of information as 
    follows:
    
                                      Table 1.--Estimated Annual Reporting Burden1                                  
    ----------------------------------------------------------------------------------------------------------------
                                                          Annual                                                    
             21 CFR Section               No. of       Frequency per   Total Annual      Hours per      Total Hours 
                                        Respondents      Response        Responses       Response                   
    ----------------------------------------------------------------------------------------------------------------
    1020.20(c)(4)                           1               1               1               1               1       
    1020.30(g)                            200               1.33          265              35           9,275       
    
    [[Page 33934]]
    
                                                                                                                    
    1020.30(h)(1) through (h)(4) and                                                                                
     1020.32(a)(1) and (g)\2\*            200               1.33          265              35           9,275       
    1020.32(g) and 1020.33(c), (d),                                                                                 
     (g)(4), (j)(1), and (j)(2)\2\*         9               1.00            9              40             360       
    1020.40(c)(9)(i) and (c)(9)(ii)         8               1.00            8              40             320       
    1030.10(c)(4)                          41               1.61           66              20           1,320       
    1030.10(c)(5)(i) through                                                                                        
     (c)(5)(iv)\2\*                        41               1.61           66              20           1,320       
    1040.10(h)(1)(i) through                                                                                        
     (h)(1)(iv)                           805               1.00          805               8           6,440       
    1040.10(h)(2)(i) and                                                                                            
     (h)(2)(ii)\2\*                       100               1.00          100               8             800       
    1040.11(a)(2)\2\*                     190               1.00          190              10           1,900       
    1040.20(d)(1), (d)(2), (e)(1),                                                                                  
     and (e)(2)                           110               1.00          110              10           1,100       
    1040.30(c)(1)                           1               1.00            1               1               1       
    1050.10(f)(1) and (f)(2)(i)                                                                                     
     through (f)(2)(iii)                   10               1.00           10              56             560       
    Disclosure Subtotal                 1,176                           1,896                          32,672       
    1020.30(d)(1) and (d)(2) and                                                                                    
     Form FDA 2579                      2,345               8.96       21,000                .30        6,300       
    1030.10(c)(6)(iii) and                                                                                          
     (c)(6)(iv)                             1               1.00            1               1               1       
    1030.10(c)(6)(iv)                       1               1.00            1               1               1       
    1040.10(a)(3)(i)                       83               1              83               3             249       
    1040.10(i)--burden in 1002.10                                                                                   
     (0910-0025)                            0                               0               0               0       
    Reports Subtotal                    2,430                          21,085                           6,551       
    Total Annual Reporting Burden       3,606               6.37       22,981               1.71       39,223       
    ----------------------------------------------------------------------------------------------------------------
    \1\There are no capital costs or operating and maintenance costs associated with this collection of information.
    \2\The total number of respondents in the reporting burden, Table 1, include respondents who have already been  
      included as a subset of another group in the table. The number of firms marked by an asterisk have been       
      included and counted as a subset of the total firms subject to reporting burden. Therefore, the number of     
      firms represented by an asterisk have not been added to the total number of respondents on the entry for      
      ``Disclosure Subtotal,'' and are not included in the total listed on the last entry of the reporting burden   
      table entitled ``Total Annual Reporting Burden.'' However, any hours of burden generated by these firms were  
      added to the total reporting burden hours on both the disclosure subtotal and total lines of the reporting    
      burden table.                                                                                                 
    
    
                                    Table 2.--Estimated Annual Recordkeeping Burden1                                
    ----------------------------------------------------------------------------------------------------------------
                                                          Annual                                                    
             21 CFR Section               No. of       Frequency per   Total Annual      Hours per      Total Hours 
                                       Recordkeepers   Recordkeeping      Records      Recordkeeper                 
    ----------------------------------------------------------------------------------------------------------------
    1020.30(q)(2)                          22               1              22               0.5            11       
    1040.10(a)(3)(ii)                      83               1              83               1              83       
    1040.30(c)(2)                           7               1               7               1               7       
    Total Annual Recordkeeping                                                                                      
     Burden                                                                                               101       
    ----------------------------------------------------------------------------------------------------------------
    \1\There are no capital costs or operating and maintenance costs associated with this collection of information.
    
        Certain labeling requirements included in these regulations are 
    either exempt from the definition of ``collection of information'' 
    under 5 CFR 1320.3(c)(2) because they are ``public disclosure[s] of 
    information originally supplied by the Federal Government to the 
    recipient for the purpose of disclosure to the public'' or have 
    negligible burden. For example, 21 CFR 1040.10(g) states that ``in 
    addition to the requirements of Secs. 1010.2 and 1010.3, each laser 
    product shall be subject to the applicable labeling requirements of 
    this paragraph.'' The provision goes on to require several cautionary 
    statements in the labeling of laser products approved under this 
    regulation, and further specifies the wording, placement and label 
    design of the required labeling.
        21 CFR 1040.30(c)(1), 1050.10(d)(1) through (d)(5), and 
    1020.10(c)(4) are labeling requirements which are exempt from OMB.
        The burden hour and cost estimates were derived by consultation 
    with FDA and industry personnel. An evaluation of the type and scope of 
    information requested was also used to derive some time estimates. For 
    example, disclosure information primarily requires time only to update 
    and maintain existing manuals. Initial development of manuals has been 
    performed except for new firms entering the industry. When information 
    is generally provided to users, assemblers, or dealers in the same 
    manual, they have been grouped together in the ``Estimated Annual 
    Reporting Burden'' table .
    
        Dated: June 11, 1998.
    William K. Hubbard,
    Associate Commissioner for Policy Coordination.
    [FR Doc. 98-16503 Filed 6-19-98; 8:45 am]
    BILLING CODE 4160-01-F
    
    
    

Document Information

Published:
06/22/1998
Department:
Food and Drug Administration
Entry Type:
Notice
Action:
Notice.
Document Number:
98-16503
Dates:
Submit written comments on the collection of information by August 21, 1998.
Pages:
33933-33934 (2 pages)
Docket Numbers:
Docket No. 98N-0364
PDF File:
98-16503.pdf